Trustees of the Welfare and Pension Funds of Local 464A, The v. Medtronic plc
- Katherine Menendez
- 0:22-cv-02197
- U.S. District Court · District of Minnesota
- 4
Trustees of Local 464A v. Medtronic plc: Judge Menendez provisionally granted plaintiffs’ request to file an amended securities-fraud complaint.
The plaintiffs may file their proposed amended securities-fraud complaint, and the defendants may file a renewed motion to dismiss challenging it.
What was alleged
The complaint alleges that Medtronic and four individual defendants made materially false and misleading statements to investors about the company's MiniMed insulin pump product line and the prospects for FDA approval of the MiniMed 780G model. The complaint alleges that defendants concealed known quality-control problems with the MiniMed 600 series pumps, including issues that the complaint alleges led to an FDA Class I recall and, later, a formal FDA warning letter in December 2021. The complaint alleges that when the truth was revealed — including through Medtronic's lowered financial guidance and disclosure that the MiniMed 780G was not expected to receive FDA approval in 2023 — the company's stock price declined, causing losses to investors. The plaintiffs claim that defendants' conduct violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
What happened
In Trustees of the Welfare and Pension Funds of Local 464A v. Medtronic plc, the court considered whether plaintiffs could file a proposed amended complaint after the court had dismissed their earlier securities-fraud complaint. The earlier dismissal found that plaintiffs had not adequately alleged actionable misrepresentations or omissions and had not shown a strong basis to infer that defendants acted knowingly or recklessly.
Plaintiffs asked for permission to file their proposed amended complaint. Defendants opposed the request, arguing that amendment would be futile because the proposed complaint still had problems with its allegations about defendants’ knowledge and other pleading defects. The court found that the proposed complaint added important details about defendants’ statements concerning approval of the 780G device, their interactions with the Food and Drug Administration, and remediation efforts related to a Form 483.
Judge Menendez provisionally granted plaintiffs’ motion to amend and permitted them to file the proposed amended complaint. The court did not decide whether the amended complaint would survive a motion to dismiss. Defendants may file a renewed motion to dismiss raising all their challenges to the new pleading.
The detailed version
- Trustees of the Welfare and Pension Funds of Local 464A, The v. Medtronic plc · No. 0:22-cv-02197
- Katherine Menendez
- Oct. 18, 2024
Background
This is a private securities-fraud case. On March 28, 2024, the court granted defendants’ motion to dismiss plaintiffs’ Consolidated Amended Complaint. The court generally concluded that plaintiffs had not alleged actionable misrepresentations or omissions and that their misrepresentation and scheme claims did not support a strong inference of scienter, meaning that defendants acted with the required wrongful state of mind.
The court did not enter judgment at that time because plaintiffs had conditionally requested permission to amend if the court rejected their position that the complaint was adequate. The court therefore allowed plaintiffs to file a motion seeking permission to amend.
Motion to Amend
Plaintiffs filed a motion for leave to file a First Amended Consolidated Class Action Complaint and attached clean and redlined versions of their proposed complaint. Defendants opposed the motion on futility grounds, arguing that the proposed complaint did not cure the deficiencies in plaintiffs’ scienter allegations and contained other pleading defects. Defendants also stated that, if amendment were allowed, they would file a more complete motion to dismiss.
The court reviewed the proposed complaint and concluded that plaintiffs had made important and potentially compelling changes addressing the court’s concerns about insufficient scienter allegations and statements that were not actionable. In particular, the proposed complaint more clearly alleged how certain defendants’ statements about progress toward approval of the 780G device could be understood as misrepresenting the nature of their interactions with the Food and Drug Administration and the possible timeline for completing remediation efforts related to a Form 483.
Court’s Reasoning
The court expressly did not decide whether the proposed amended complaint would survive a challenge under Rule 12(b)(6), which tests whether a complaint states a legally sufficient claim. It found that rejecting the proposed complaint for failure to state a claim was not a foregone conclusion.
Because defendants planned a more complete challenge to the proposed amended complaint, the court determined that it would be inefficient to decide defendants’ futility arguments and then potentially apply the same legal standard again in a renewed motion to dismiss. The court exercised its discretion to allow the amendment provisionally and address the complete set of challenges in a renewed motion to dismiss.
Disposition
The court provisionally GRANTED plaintiffs’ Motion for Leave to File a First Amended Consolidated Class Action Complaint, as stated in the order. Plaintiffs were required to file the First Amended Consolidated Class Action Complaint in the same form as the proposed complaint within three business days of the order. Within fourteen days, the parties were required to meet and confer about a briefing schedule for defendants’ renewed motion to dismiss and file a stipulation addressing that schedule. The court stated that it would not hold a hearing on the renewed motion unless it later determined that additional argument was necessary.
The order did not decide whether the amended complaint states a claim or whether defendants’ renewed motion to dismiss will succeed.
Read the full 4-page opinion on CourtListener, the free public archive maintained by the Free Law Project.